{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["De Rosa L"],"pubmed_abstract":["Epidermolysis bullosa (EB) is a group of devastating genetic diseases characterized by skin and mucosal fragility and formation of blisters, which develop either spontaneously or in response to minor mechanical trauma. There is no definitive therapy for any form of EB. Intermediate junctional EB (JEB) caused by mutations in the gene <i>LAMB3</i> has been the first genetic skin disease successfully tackled by <i>ex vivo</i> gene therapy. Here, we present a multicenter, open-label, uncontrolled phase II/III study that aims at confirming the efficacy of Hologene 5, a graft consisting of cultured transgenic keratinocytes and epidermal stem cells and meant to combine cell and gene therapy for the treatment of <i>LAMB3</i>-related JEB. Autologous clonogenic keratinocytes will be isolated from pa"],"journal":["Frontiers in genetics"],"pagination":["705019"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8440932"],"repository":["biostudies-literature"],"pubmed_title":["Hologene 5: A Phase II/III Clinical Trial of Combined Cell and Gene Therapy of Junctional Epidermolysis Bullosa."],"pmcid":["PMC8440932"],"pubmed_authors":["Bodemer C","Schneider H","Enzo E","De Luca M","Zardi G","De Rosa L","Magnoni C"],"additional_accession":[]},"is_claimable":false,"name":"Hologene 5: A Phase II/III Clinical Trial of Combined Cell and Gene Therapy of Junctional Epidermolysis Bullosa.","description":"Epidermolysis bullosa (EB) is a group of devastating genetic diseases characterized by skin and mucosal fragility and formation of blisters, which develop either spontaneously or in response to minor mechanical trauma. There is no definitive therapy for any form of EB. Intermediate junctional EB (JEB) caused by mutations in the gene <i>LAMB3</i> has been the first genetic skin disease successfully tackled by <i>ex vivo</i> gene therapy. Here, we present a multicenter, open-label, uncontrolled phase II/III study that aims at confirming the efficacy of Hologene 5, a graft consisting of cultured transgenic keratinocytes and epidermal stem cells and meant to combine cell and gene therapy for the treatment of <i>LAMB3</i>-related JEB. Autologous clonogenic keratinocytes will be isolated from pa","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2025-05-29T19:05:16.809Z","creation":"2022-02-11T11:12:32.814Z"},"accession":"S-EPMC8440932","cross_references":{"pubmed":["34539738"],"doi":["10.3389/fgene.2021.705019"]}}